Physician profile
Hayan Moualla
NPI 1760682835
$2,727.01
in general payments reported to CMS, 2019-2025
19 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $187 · 2021: $589 · 2022: $450 · 2023: $14.28 · 2024: $36.96 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,100 · Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,100.00 |
| Food and Beverage | $300.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,123.84 | 2025 | Jakafi |
| Beigene, LTD. | $525.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $250.00 | 2022 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $73.19 | 2020-2025 | |
| Celgene Corporation | $58.03 | 2023-2025 | Opdivo, Pomalyst |
| Aveo Pharmaceuticals, INC. | $34.07 | 2024-2025 | |
| Glaxosmithkline, LLC. | $30.25 | 2025 | Zejula |
| Janssen Biotech, INC. | $23.65 | 2025 | Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $18.63 | 2025 | Opdivo |
| Genzyme Corporation | $18.39 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.35 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.89 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $17.65 | 2021 | |
| Pharmacosmos Therapeutics INC. | $17.33 | 2025 | Monoferric |
| Abbvie INC. | $13.82 | 2025 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayan Moualla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.